Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Form 8.5 (EPT/NON-RI)

21 Mar 2025 08:36

RNS Number : 6665B
Cavendish Securities PLC
21 March 2025
 

FORM 8.5 (EPT/NON-RI)

  

 

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Cavendish Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Tissue Regenix Group Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Tissue Regenix Group Plc

(d) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

20/03/2025

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

ORD 0.1P

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

92376

 

 

 

 

0.13

 

 

 

 

 

 

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

92376

 

 

0.13

 

 

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

ORD 0.1P

 

 

 

 

 

 

 

 

Sales

 

15000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

37.9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

37.9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

21/03/2025

Contact name:

Nancy Dyer

Telephone number:

0207 220 0594

 

 

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEOUAOWRVOUOURR
Date   Source Headline
7th Jul 20113:52 pmRNSIssue of Share Options
5th Jul 20111:30 pmRNSIssue of Equity
22nd Jun 20118:35 amRNSReceives EUR280,000 Grant Funding
13th Jun 20117:00 amRNSDirectorate Appointment
3rd Jun 201110:02 amRNSAGM Statement
11th May 20117:00 amRNSPositive Results in Clinical Evaluation of dCELL
4th May 20117:00 amRNSFinal Results
21st Apr 20117:00 amRNSTissue Regenix enters commercialisation agreement
29th Mar 20117:00 amRNSDirectorate Change
10th Mar 20117:00 amRNSNotice of allowance of patent received
4th Jan 201111:27 amRNSHolding(s) in Company
30th Dec 20109:05 amRNSHolding(s) in Company
23rd Dec 201012:44 pmRNSChange of Adviser
21st Dec 201010:12 amRNSAdviser - Change of Name
16th Dec 20107:00 amRNSResearch Update
10th Dec 20109:20 amRNSChange of Adviser
26th Nov 20103:12 pmRNSChange of Registered Office
23rd Nov 20105:18 pmRNSIssue of Equity
20th Oct 20107:00 amRNSHalf Yearly Report
18th Aug 20102:19 pmRNSHolding(s) in Company
10th Aug 20107:00 amRNSCE Mark Grant
5th Aug 20103:43 pmRNSPatents approved
1st Jul 201010:38 amRNSHolding(s) in Company
29th Jun 20104:37 pmRNSIssue of Equity
29th Jun 20108:06 amRNSFirst day dealings in Tissue Regenix
29th Jun 20107:00 amRNSFirst Day of Dealings
28th Jun 20102:20 pmRNSResult of General Meeting
10th Jun 20103:39 pmRNSSch 1 - Oxeco (to be renamed Tissue Regenix Group)
3rd Jun 20107:00 amRNSAcquisition
21st Apr 201011:20 amRNSResult of AGM
26th Mar 20107:00 amRNSFinal Results
11th Jan 20105:05 pmRNSHolding(s) in Company
23rd Dec 20091:49 pmRNSHolding(s) in Company
23rd Dec 200912:07 pmRNSHolding(s) in Company
22nd Dec 20094:33 pmRNSHolding(s) in Company
17th Dec 20093:50 pmRNSHolding(s) in Company
17th Dec 20092:47 pmRNSHolding(s) in Company
9th Dec 20099:28 amRNSInvesting Policy
23rd Oct 20097:00 amRNSInterim financial report
25th Aug 20092:30 pmRNSHolding(s) in Company
23rd Jul 20097:00 amRNSClosure of subsidiary business
2nd Jun 200912:00 pmRNSAppointment of Non-Executive Director
26th May 20093:00 pmRNSChange of Nominated Adviser Name
20th Apr 20097:00 amRNSFinal Results
24th Mar 200910:18 amRNSAppointment of Broker
18th Mar 200911:54 amRNSStrategic Review and Directorate Change
19th Nov 20087:00 amRNSDirectorate Change
16th Oct 20087:00 amRNSInterim Results
9th Jul 200812:39 pmRNSHolding(s) in Company
29th May 200812:10 pmRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.